Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
-
Disturbed sleep is a common complaint in patients with rheumatoid arthritis (RA). The majority of the research investigating relationships between sleep and patient-reported outcomes in RA has focused on pain and depression. Poor sleep may also affect disability, though this association has not been explored in RA. The present study represents a cross-sectional examination of the relationship between sleep quality and functional disability in 162 patients with RA. Depression, pain severity, and fatigue were examined as separate mediators of the relationship between sleep quality and disability. ⋯ Sleep quality has an indirect effect on functional disability through its relationship with pain severity and fatigue. Future research should investigate whether improvements in sleep can reduce disability in patients with RA.
-
To develop a polysomnographic video-based scale for rating the severity of REM sleep behavior disorder (RBD), to classify the severity of RBD and to determine the intraindividual variability of RBD in patients with Parkinson disease (PD). ⋯ The RBD severity scale (RBDSS) is a reliable, easy-to-use tool for assessing motor events during REM sleep with PSG. Severity and phenomenology of RBD shows a significant variability in the individual PD patient.
-
Comparative Study
Mallampati class is not useful in the clinical assessment of sleep clinic patients.
To assess the utility of Mallampati class, a simple grade of oropharyngeal appearance used to assess difficulty of intubation, to predict severe obstructive sleep apnea and absence of OSA (rule in severe OSA and rule out OSA). ⋯ Mallampati class is associated with AHI but does not significantly modify likelihood of severe OSA or absence of OSA. As such, it is of limited use to "rule in" severe OSA or "rule out OSA" in the sleep clinic population.
-
Randomized Controlled Trial Multicenter Study Comparative Study
The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy.
To further explore the effects of sodium oxybate (SXB) administration on nocturnal sleep in narcolepsy patients during a double-blind, placebo-controlled, parallel group study conducted with 228 adult patients with narcolepsy/cataplexy in the United States, Canada, and Europe. ⋯ The nightly administration of SXB to narcolepsy patients significantly impacts measures of slow wave sleep, wake after sleep onset, awakenings, total sleep time, and stage 1 sleep in a dose-related manner. The frequency and severity of narcolepsy symptoms decreased with treatment.